Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels | Completed | Type 2 Diabetes Mellitus, Obesity | Drug - rosiglitazone | Baskent University, Other | Female | 45 Years - 65 Years | Phase 4 | Interventional | We aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women. | |
|
Clinicaltrials.gov | Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS | Completed | Obesity, Polycystic Ovary Syndrome | Drug - Sibutramine | Hippocration General Hospital, Other | Female | 18 Years - 40 Years | Phase 4 | Interventional | Studies on the effect of sibutramine, an anti-obesity drug, on hormonal and metabolic features of women with polycystic ovary syndrome (PCOS) are lacking. The objective of this study is to examine the effect of sibutramine plus hypocaloric diet on body composition, hormonal and metabolic parameters and insulin resistance in obese patients with PCOS. Overweight and obese women with PCOS were placed in a hypocaloric diet plus sibutramine (10 mg/day) for the first month and then on a hypocaloric diet plus sibutramine (10 mg/day) or hypocaloric diet only for the subsequent 6 months. The main outcome measures are: Body composition, hormonal and metabolic features and insulin sensitivity (OGTT) at baseline, at 3 and 6 months of treatment. | |
|
Clinicaltrials.gov | Mechanism of Growth Hormone Effects on Adipose Tissue | Completed | Obesity | Drug - rhGH | Pennington Biomedical Research Center, Other | Male | 40 Years - 70 Years | Phase 4 | Interventional | Growth hormone treatment in humans has been shown to decrease body fat. This study aims to determine what adipose tissue depots are affected by GH and what is the mechanism. | |
Clinicaltrials.gov | Optimizing Body Composition for Function in Older Adults | Completed | Obesity, Overweight With Indications for Weight Loss | Drug, Behavioral, Behavioral, Drug - Pioglitazone, Resistance exercise training to maximize muscle power, Hypocaloric diet, Placebo | Wake Forest University Health Sciences, Takeda Pharmaceuticals North America, Inc., National Institute on Aging (NIA), Other, Industry, NIH | 65 Years - 79 Years | Phase 4 | Interventional | The purpose of this pilot study is to compare two strategies intended to improve the health of overweight older adults by improving body composition. One strategy, resistance training, is designed to preserve skeletal muscle mass. The other strategy, the use of a PPAR-γ agonist, is designed to enhance the loss of fat from visceral and skeletal depots. These strategies will be used in conjunction with a hypocaloric diet and will be compared to a hypocaloric diet alone to determine if either of these strategies are superior in reducing visceral fat and preserving muscle mass. | ||
|
Clinicaltrials.gov | The Effect of Xenical on Weight and Risk Factors | Completed | Obesity, Heart Diseases | Drug - Orlistat | University of British Columbia, Other | 19 Years - N/A | Phase 4 | Interventional | The purpose of this study is to determine the effect of using the weight loss medication Xenical (generic name - orlistat) on weight loss and change in heart disease risk factors in patients of the Healthy Heart Program Lipid Clinic at St. Paul's Hospital over a three month period. Xenical works by blocking the body's absorption of dietary fat in the gut, allowing it to pass through to be excreted, therefore reducing the intake of fat and calories. This is a pilot study supported by Hoffmann-La Roche Limited which produces Xenical. The aim is to investigate whether weight loss will also result in reductions in heart disease risk factors that may allow for less of a need for medications controlling lipid levels, hypertension and plasma glucose. | ||
|
Clinicaltrials.gov | Long-term Effectiveness of the Antiobesity Medication Phentermine | Not yet recruiting | Obesity, Obesity, Drug, Lifestyle, Healthy | Behavioral, Drug - Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG | Wake Forest University Health Sciences, Johns Hopkins University, Kaiser Permanente, HealthPartners Institute, The University of Texas Health Science Center, Houston, Biomedical Research Institute of New Mexico, WW International Inc., KVK-Tech, Inc., National Heart, Lung, and Blood Institute (NHLBI), Other, Other, Other, Other, Other, Other, Other, Other, NIH | 18 Years - 70 Years | Phase 4 | Interventional | The purpose of this research study is to understand the long-term effects of the drug phentermine on weight, blood pressure, other health outcomes, and safety. Phentermine has been approved by the US Food and Drug Administration (FDA) for weight management since 1959, but it has not been approved for long-term use (i.e., treatment lasting more than 12 weeks). This trial is designed to learn about the long-term effects of phentermine for up to 2 years because obesity is a chronic disease and expert guidelines recommend long-term use of anti-obesity medications as one treatment option. | ||
|
Clinicaltrials.gov | Quality Assessment of Orotracheal Intubation Without Neuromuscular Blocking Agents in Obese Patients | Not yet recruiting | Obesity, Bariatric Surgery Candidate, Intubation Complication | Drug, Drug - Remifentanil Injection, Remifentanil Injection plus 30% | University Hospital, Toulouse, Other | 18 Years - 60 Years | Phase 4 | Interventional | This study will assess the condition of orotracheal intubation in obese patients undergoing an elective bariatric surgery without the use of neuromuscular blocking agents. During the induction of general anesthesia, Propofol - Remifentanil combination will be used. The patients will be randomized in 2 groups with different doses of Remifentanil. | ||
|
Clinicaltrials.gov | Effects of Capsimax on Appetite, Energy Intake and Blood Pressure | Completed | Obesity, Body Weight, Weight Loss, Overweight | Drug, Other - Capsimax, Energy restriction | Laval University, OmniActive Health Technologies, Other, Industry | Female | 18 Years - 50 Years | Phase 4 | Interventional | Obesity is an ongoing major public health problem in most countries of the world for which the agrifood industry still remains criticized because of the abundant offer of high sugar-lipid-energy dense foods, particularly in the fast-food sector. The resulting societal pressure on the food industry probably explains in part the efforts that have been deployed to seek natural active ingredients and to develop functional foods favorably influencing energy balance. Capsaicin is a food non-nutrient constituent that was shown to decrease appetite sensations and subsequent energy intake. The measurement of heart rate variability revealed an association between the increase in sympathetic nervous system (SNS) activity and the satiating effects induced by capsaicin. This is concordant with the observation that pre-prandial intake of capsaicin, be it in capsules or diluted in tomato juice, increased satiety and reduced energy intake. The objective of this study is to evaluate the long effects of Capsimax on appetite sensations and energy expenditure under conditions of moderate energy restriction and to evaluate the long-term effects of Capsimax on energy intake and expenditure under conditions of moderate energy restriction. | |
|
Clinicaltrials.gov | Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity | Active, not recruiting | Obesity | Drug, Behavioral, Behavioral - Phentermine 37.5 Mg, Dietary program, Exercise program | The Cleveland Clinic, Other | 18 Years - 65 Years | Phase 4 | Interventional | This study will study the effects associated with the prescription of phentermine in a virtual setting, comparing with prescription of phentermine via a standard face-to-face visit for patients with obesity or overweight. | ||
|
Clinicaltrials.gov | Empagliflozin and Atrial Fibrillation Treatment | Not yet recruiting | Atrial Fibrillation, Heart Failure, Obesity, Diabetes Mellitus | Drug, Other - Empagliflozin, Placebo | Miulli General Hospital, Other | 18 Years - 80 Years | Phase 4 | Interventional | The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, in patients with diabetes mellitus or overweight, heart failure and atrial fibrillation. | ||
|
Clinicaltrials.gov | Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker | Recruiting | Obesity | Drug, Drug, Other - Phentermine-Topiramate Extended Release, Placebo, Online support system | Mayo Clinic, Other | 18 Years - 75 Years | Phase 4 | Interventional | Researchers are assessing the effects of weight loss medication vs a placebo among participants provided with a wearable activity tracker, digital wellness devices and lifestyle recommendations. | ||
|
Clinicaltrials.gov | Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery | Withdrawn | Obesity | Drug, Other - Naltrexone/bupropion, Lifestyle | Oslo University Hospital, Orexigen Therapeutics, Inc, Other, Industry | 18 Years - 65 Years | Phase 4 | Interventional | Limited/poor weight loss and weight regain are concerns following bariatric surgery, and weight regain may increase the risk for relapse of comorbidities related to obesity. Medications for weight reduction may assist further weight loss, and support weight maintenance, with positive effects on comorbidities. This pilot study will examine the effect of naltrexone/bupropion and lifestyle advice versus lifestyle advice alone for 7 months in patients with a suboptimal weight trajectory (either little weight loss or weight regain) 2 years or later following bariatric surgery. | ||
|
Clinicaltrials.gov | Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants With Type 2 Diabetes | Recruiting | Type 2 Diabetes, Obesity | Drug, Drug, Drug, Drug, Drug, Drug - 0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min, Glucagon 12.5ng/kg/min and 0.9% saline, 0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min, Glucagon 12.5ng/kg/min | Cambridge University Hospitals NHS Foundation Trust, Antaros Medical, Other, Industry | 18 Years - 99 Years | Phase 4 | Interventional | The study seeks to explore the cardiovascular effects of co-agonism at the glucagon and (glucagon-like peptide-1) GLP-1 receptor. Glucagon and exenatide will be intravenously infused into participants with type 2 diabetes (T2DM). Overall, the aim of the study is to further the investigator's understanding on the role these endogenous substances have on normal cardiac physiology, myocardial energetics and myocardial glucose uptake through a series of PET and MRI imaging studies | ||
|
Clinicaltrials.gov | Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol | Enrolling by invitation | Obesity, Bariatric Surgery, Roux-en Y Gastric Bypass | Procedure, Drug, Procedure, Drug, Drug, Drug, Other - Digestive biopsy, Carvedilol 25mg, Serial blood sampling for PK analysis, Metoprolol 100 mg for CYP2D6 phenotyping, Simvastatin 40mg, Midazolam 2 mg for CYP3A4 phenotyping, Genotyping | Natalia Valadares de Moraes, Fundação de Amparo à Pesquisa do Estado de São Paulo, University of Sao Paulo, Other, Other, Other | 18 Years - 65 Years | Phase 4 | Interventional | Obesity affects more than 1 in 3 adults in the U.S. It is commonly associated with reduced quality of life and complications such as metabolic syndrome, heart disease, high blood pressure and sleep disorders. The gastric bypass, also known as Roux-en-Y gastric bypass (RYGB), is one of the most common weight-loss surgeries due to the reliable and long-lasting weight loss and the effective remission of obesity-associated conditions. Although the impact of obesity on absorption, distribution, metabolism and excretion has been documented for several drugs, label recommendations might not account for specific population subgroups, specially morbidly obese patients and obese patients post-bariatric surgery. This study aims to investigate the impact of obesity and RYGB surgery on the kinetic disposition of simvastatin (Study A) and carvedilol (Study B). | ||
|
Clinicaltrials.gov | Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum | Unknown status | Obesity, Wound Infection, Pregnancy | Device, Other - Kerlix-AMD, placebo--normal gauze | Lawson Health Research Institute, Other | Female | 15 Years - 50 Years | Phase 4 | Interventional | Pregnant women with BMI>40 will be approached for participation in a study to reduce the rate of post-operative wound infection from C-section. Women will be randomized to a commonly used wound product (Kerlix-AMD) which consists of a PHMB-impregnated gauze versus normal gauze, and rates of post-operative surgical site infection will be assessed. Women with a planned procedure will also be randomized to applying Kerlix versus gauze for 3 days pre-operatively to determine if this improves outcomes as well. | |
|
Clinicaltrials.gov | Auricular Acupuncture in the Treatment of Obesity | Completed | Obesity | Other, Other - Auricular Acupuncture, Sham Acupuncture | Mike O'Callaghan Military Hospital, U.S. Fed | 18 Years - N/A | Phase 4 | Interventional | Male and female DoD beneficiaries ages 18 years or older, who are referred for a standard of care weight loss intervention for treatment of obesity will be recruited. Subjects will be randomized into one of two groups receiving either a standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point or receiving a standard of care weight loss intervention plus sham auricular acupuncture. Subjects will receive treatment in accordance with their randomization group for 12 weeks then have one additional follow up visit at week 24. The following measures will be obtained: height, weight, waist circumference, and Body Mass Index will be calculated. | ||
|
Clinicaltrials.gov | Pharmacokinetics of Carbapenem Antibiotics in Obese Patients. | Completed | Obesity | Procedure, Procedure - microdialysis catheter, microdialysis catheter | University of Ulm, Other | 18 Years - N/A | Phase 4 | Interventional | Tissue kinetics of ertapenem and meropenem in fatty tissue, intraperitoneal fluid and plasma. | ||
|
Clinicaltrials.gov | Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study | Withdrawn | Obesity, Insulin Resistance | Drug, Drug - pioglitazone, Metformin | University of Minnesota, Other | 10 Years - 17 Years | Phase 4 | Interventional | The primary objective of this study is to examine the effects of four months of pioglitazone vs. metformin treatment on HDL cholesterol, triglycerides, blood pressure, insulin resistance, endothelial function, arterial stiffness, adipokines, oxidative stress, and blood biomarkers of endothelial activation in obese insulin resistant children. 30 obese children with elevated fasting insulin levels will be randomly assigned to pioglitazone or metformin for 16 weeks. Change in clinical variables over the 16-week study period will be compared between groups. | ||
|
Clinicaltrials.gov | The Effect of Liraglutide on the GIT | Unknown status | Obesity | Drug, Drug - 0.6 mg Liraglutide, Placebo | Universitaire Ziekenhuizen Leuven, Other | 18 Years - 65 Years | Phase 4 | Interventional | Liraglutide is a glucose-like peptide 1 agonist, currently used as an effective weight-loss treatment. Its mechanism of action has not yet been elucidated. We want to investigate whether liraglutide affects MMC activity, gastrointestinal hormone release, glucose whole blood levels, hunger ratings and ad libitum food intake in healthy volunteers. | ||
|
Clinicaltrials.gov | Effect of Hydroxychloroquine Sulphate in Healthy Lean Females | Unknown status | Obesity | Drug, Drug - Hydroxychloroquine Sulphate, Placebo | Universitaire Ziekenhuizen Leuven, Other | Female | 18 Years - 65 Years | Phase 4 | Interventional | The effect of an acute administration of hydroxychloroquine sulphate will be investigated on hedonic food intake, appetite related sensations and gastrointestinal hormone release in healthy female subjects. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
